[Ip-health] Proposals for the section in the Paris Accord on Medical research and development, June 16, 2006.

[James Love]

--
[ Picked text/plain from multipart/alternative ]


Begin forwarded message:

From: James Love <james.love@cptech.org>
Date: June 16, 2006 8:48:56 AM EDT
To: a2k discuss list <a2k@lists.essential.org>
Subject: [A2k] Proposals for the section in the Paris Accord on
Medical research and development, June 16, 2006.

This reflects comments received to date.

Proposals for the section in the Paris Accord on Medical research and
development, June 16, 2006.

1.	Research and development is a necessary and valued component of
the health care system.

2.	A number of different institutions are essential for the support
of medical R&D, including government, intergovernmental, non-
government not-for-profit and for-profit organizations.

3.	The systems for supporting research and development of new drugs
should ensure sustainable sources of finance that support employment
in R&D organizations, but also should not undermine the goal of
access for all for new medical inventions.

4.	Systems for stimulating R&D should address areas of greatest
health need and public interest.

5.	Separation of markets for innovation and products that incorporate
those innovations.  When possible and appropriate, the elements of
the current systems of stimulating R&D through high prices for
[essential] medical products (through such measures as market
exclusivity for innovators), should be replaced with new systems that
reward developers of new products directly for improved health care
outcomes.   This can be easily accomplished when systems of public or
private insurance exist for medicine, and when it is feasible to
estimate the impact of new medicines on health outcomes.

6.	There is also a need to expand methods of funding projects that
support open research, the development of databases and other
research tools, as well as high-risk R&D projects that are likely to
be useful for follow-on innovation.

7.	Science depends upon access to knowledge.  Hoarding of data and
materials must be discouraged.

8.	Intellectual property rules should not prevent experimental use of
inventions or materials, nor should they discourage or prevent
investments in any field of invention.

9.	National governments should eliminate visa restrictions that limit
the ability of students to study at universities in another nation,
or restrict the ability of scientists or engineers to participate in
conferences or gain experience at firms in another nation.

10.	Methods of protecting investments in clinical trials for new
medicines should not prevent governments from making medicines
available at affordable prices or require unethical or unnecessary
replication of human experiments.

11.	Individuals and communities that collaborate in scientific
research should receive appropriate recognition for contributions to
new scientific discoveries.

12.	Governments must support global agreements to share in the costs
of evaluating new medicines.  Such testing should be transparent, and
funded by sources that do not have incentives to distort or
misrepresent findings, and which address the most useful scientific
and medical questions.

13.	Patients should freely share biological materials, and consider
participation in clinical trials to test new medicines, with the
expectation that new scientific advancements will be accessible to
all, that clinical trials and other experiments follow appropriate
ethical standards, and that the trials are reported to public
databases, in order to provide for greater transparency of the
scientific evidence, subject to appropriate protections of personal
privacy.


---------------------------------
James Love, CPTech / www.cptech.org / mailto:james.love@cptech.org /
tel. +1.202.332.2670 / mobile +1.202.361.3040

"If everyone thinks the same: No one thinks."  Bill Walton


_______________________________________________
A2k mailing list
A2k@lists.essential.org
http://lists.essential.org/mailman/listinfo/a2k


---------------------------------
James Love, CPTech / www.cptech.org / mailto:james.love@cptech.org /
tel. +1.202.332.2670 / mobile +1.202.361.3040

"If everyone thinks the same: No one thinks."  Bill Walton